Shandong Xinhua Pharmaceutical Past Earnings Performance
Past criteria checks 2/6
Shandong Xinhua Pharmaceutical has been growing earnings at an average annual rate of 11.4%, while the Pharmaceuticals industry saw earnings growing at 5.7% annually. Revenues have been growing at an average rate of 9.5% per year. Shandong Xinhua Pharmaceutical's return on equity is 9.1%, and it has net margins of 5.4%.
Key information
11.4%
Earnings growth rate
9.0%
EPS growth rate
| Pharmaceuticals Industry Growth | 5.6% |
| Revenue growth rate | 9.5% |
| Return on equity | 9.1% |
| Net Margin | 5.4% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Shandong Xinhua Pharmaceutical (HKG:719) Is Paying Out A Larger Dividend Than Last Year
Jun 28
Insufficient Growth At Shandong Xinhua Pharmaceutical Company Limited (HKG:719) Hampers Share Price
Jan 23Shandong Xinhua Pharmaceutical (HKG:719) Takes On Some Risk With Its Use Of Debt
Mar 07Is Shandong Xinhua Pharmaceutical (HKG:719) Using Too Much Debt?
Nov 18These 4 Measures Indicate That Shandong Xinhua Pharmaceutical (HKG:719) Is Using Debt Extensively
Jul 27Shandong Xinhua Pharmaceutical (HKG:719) Has Affirmed Its Dividend Of HK$0.18
Jul 04Estimating The Intrinsic Value Of Shandong Xinhua Pharmaceutical Company Limited (HKG:719)
Mar 09We Think Shandong Xinhua Pharmaceutical (HKG:719) Can Stay On Top Of Its Debt
Dec 21Does Shandong Xinhua Pharmaceutical (HKG:719) Deserve A Spot On Your Watchlist?
Apr 06What Kind Of Shareholders Own Shandong Xinhua Pharmaceutical Company Limited (HKG:719)?
Mar 19Is Shandong Xinhua Pharmaceutical (HKG:719) A Risky Investment?
Feb 26Are Shandong Xinhua Pharmaceutical's (HKG:719) Statutory Earnings A Good Guide To Its Underlying Profitability?
Feb 05
Shandong Xinhua Pharmaceutical (HKG:719) Share Prices Have Dropped 43% In The Last Three Years
Jan 18Is Shandong Xinhua Pharmaceutical Company Limited (HKG:719) A Smart Pick For Income Investors?
Dec 29Do Institutions Own Shandong Xinhua Pharmaceutical Company Limited (HKG:719) Shares?
Dec 14Is Shandong Xinhua Pharmaceutical (HKG:719) Using Too Much Debt?
Nov 26Revenue & Expenses Breakdown
How Shandong Xinhua Pharmaceutical makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 8,337 | 449 | 1,089 | 405 |
| 30 Jun 24 | 8,161 | 492 | 1,155 | 427 |
| 31 Mar 24 | 7,936 | 487 | 1,189 | 449 |
| 31 Dec 23 | 8,101 | 497 | 1,298 | 419 |
| 30 Sep 23 | 8,547 | 510 | 1,354 | 428 |
| 30 Jun 23 | 8,511 | 486 | 1,347 | 413 |
| 31 Mar 23 | 8,311 | 454 | 1,325 | 379 |
| 01 Jan 23 | 7,503 | 411 | 1,111 | 346 |
| 30 Sep 22 | 7,073 | 357 | 980 | 352 |
| 30 Jun 22 | 6,673 | 343 | 900 | 340 |
| 31 Mar 22 | 6,623 | 357 | 908 | 343 |
| 31 Dec 21 | 6,560 | 349 | 931 | 341 |
| 30 Sep 21 | 6,307 | 364 | 935 | 338 |
| 30 Jun 21 | 6,271 | 353 | 992 | 311 |
| 31 Mar 21 | 6,068 | 339 | 957 | 301 |
| 31 Dec 20 | 6,006 | 325 | 944 | 298 |
| 30 Sep 20 | 5,814 | 305 | 982 | 261 |
| 30 Jun 20 | 5,769 | 323 | 990 | 260 |
| 31 Mar 20 | 5,682 | 310 | 1,049 | 253 |
| 31 Dec 19 | 5,606 | 300 | 1,105 | 235 |
| 30 Sep 19 | 5,716 | 303 | 1,107 | 229 |
| 30 Jun 19 | 5,680 | 281 | 1,072 | 233 |
| 31 Mar 19 | 5,457 | 264 | 1,012 | 201 |
| 31 Dec 18 | 5,245 | 255 | 924 | 187 |
| 30 Sep 18 | 5,023 | 229 | 859 | 172 |
| 30 Jun 18 | 4,800 | 226 | 809 | 151 |
| 31 Mar 18 | 4,638 | 226 | 710 | 204 |
| 31 Dec 17 | 4,516 | 210 | 725 | 161 |
| 30 Sep 17 | 4,491 | 207 | 718 | 130 |
| 30 Jun 17 | 4,420 | 183 | 762 | 97 |
| 31 Mar 17 | 4,306 | 154 | 799 | 0 |
| 31 Dec 16 | 4,015 | 122 | 724 | 0 |
| 30 Sep 16 | 3,800 | 110 | 667 | 0 |
| 30 Jun 16 | 3,647 | 103 | 624 | 0 |
| 31 Mar 16 | 3,602 | 89 | 611 | 0 |
| 31 Dec 15 | 3,597 | 83 | 611 | 0 |
| 30 Sep 15 | 3,604 | 64 | 613 | 0 |
| 30 Jun 15 | 3,678 | 36 | 593 | 0 |
| 31 Mar 15 | 3,653 | 62 | 604 | 0 |
| 31 Dec 14 | 3,590 | 51 | 565 | 0 |
| 30 Sep 14 | 3,769 | 52 | 614 | 0 |
| 30 Jun 14 | 3,635 | 74 | 589 | 0 |
| 31 Mar 14 | 3,588 | 50 | 544 | 0 |
| 31 Dec 13 | 3,391 | 39 | 501 | 0 |
Quality Earnings: 719 has high quality earnings.
Growing Profit Margin: 719's current net profit margins (5.4%) are lower than last year (6%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 719's earnings have grown by 11.4% per year over the past 5 years.
Accelerating Growth: 719's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: 719 had negative earnings growth (-12%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (6.4%).
Return on Equity
High ROE: 719's Return on Equity (9.1%) is considered low.